GlassScriptPhysician profile
Bala Davuluri
NPI 1407010754
$1,956.25
in general payments reported to CMS, 2019-2025
22 companies · $61.80 in 2025
The $61.80 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $544 · 2023: $847 · 2024: $503 · 2025: $61.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,412.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $501.42 | 2022-2025 | Qulipta, Ubrelvy, Botox |
| Novartis Pharmaceuticals Corporation | $144.99 | 2022-2025 | |
| Sk Life Science, INC. | $134.02 | 2022-2023 | |
| Lilly USA, LLC | $131.47 | 2022-2024 | Emgality, Reyvow |
| Biogen, INC. | $128.86 | 2022-2024 | Tysabri, Skyclarys, Vumerity |
| Eisai INC. | $123.76 | 2023 | |
| Ucb, INC. | $102.57 | 2022-2024 | Briviact, Fintepla |
| Pfizer INC. | $94.51 | 2023-2024 | |
| Acadia Pharmaceuticals INC | $89.41 | 2022-2023 | Nuplazid |
| Medtronic, INC. | $84.73 | 2023-2024 | Intellis Adaptivestim, Vanta Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $66.33 | 2022-2024 | Austedo Xr, Austedo |
| Amgen INC. | $49.41 | 2022-2023 | Aimovig |
| Argenx US, INC. | $47.62 | 2024 | Vyvgart |
| Acorda Therapeutics, INC | $41.74 | 2023-2024 | Inbrija |
| Xeris Pharmaceuticals, INC. | $41.68 | 2022-2023 | Keveyis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $40.35 | 2022 | |
| Janssen Pharmaceuticals, INC | $37.31 | 2022 | |
| Genzyme Corporation | $30.31 | 2023 | |
| Genentech USA, INC. | $29.06 | 2024 | Ocrevus |
| Avion Pharmaceuticals | $15.56 | 2022 | |
| Lundbeck LLC | $13.95 | 2023 | Vyepti |
| Life Molecular Imaging LTD | $7.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bala Davuluri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.